Fig. 6

Mechanistic target of MEK attenuates Gab2-induced tumor growth and angiogenesis. a and b SW480-Gab2 cells were treated (U0126) or not (Vehicle) with 20 μM U0126 during 12 h after which proteins and mRNA were analyzed the expression of c-Myc and VEGF by western blot and qRT-PCR, respectively. c SW480-Gab2 cells were treated (U0126) or not (Vehicle) with 20 μM U0126, and the number of viable cells was determined 24, 48 and 72h later. d-g SW480-Gab2 cells were injected into nude mice subcutaneously. Mice were treated (U0126) or not (Vehicle) with U0126 every 5 days via tail vein for 5 weeks (n = 6 mice per group). Primary tumor growth was examined by measuring tumor volume every 7 days. After 35 days, tumor weight was analyzed, and xenograft tumors were analyzed for Ki67 and CD34 using immunohistochemistry. h Proteins were extracted from xenografts and VEGF levels were measured by western blot. The levels of VEGF were calculated. The data are representative of at least three different experiments ± SEM. NS: No statistical significance; *P < 0.05